Preliminary data published after the completion of our survey suggest that patients with KRAS mutated and PD-L1-negative NSCLC treated with (chemo)immunotherapy experience worse OS, with this association being largely driven by STK11 and KEAP1 co-mutation, which are enriched in PD-L1 negative NSCLC; indeed, patients with triple KRAS, KEAP, and STK11 mutations and no PD-L1 expression experienced the worst outcomes [45]. The gene discussed is STK11; the disease is non-small cell lung carcinoma.